Gensia Laboratories Ltd., a wholly owned generic drugsubsidiary of Gensia Pharmaceuticals Inc. (NASDAQ:GNSA), hasreceived an abbreviated new drug application approval fromthe Food and Drug Administration to market intravenoustobramycin in two dosage strengths. The drug is a broad-spectrum antibiotic used in hospitals primarily to treat gram-negative infections associated with sepsis, the urinary tract andgastrointestinal system. Gensia shares gained $1.25 to $61.50.
(c) 1997 American Health Consultants. All rights reserved.